Search Results

You are looking at 51 - 60 of 1,744 items for :

  • "chemotherapy" x
Clear All
Full access

Paul J. Speicher, Lin Gu, Xiaofei Wang, Matthew G. Hartwig, Thomas A. D'Amico and Mark F. Berry

Background Adjuvant chemotherapy (AC) after resection of stages II through IIIA non–small cell lung cancer (NSCLC) has repeatedly been shown to improve survival. 1 – 6 NCCN and ASCO therefore both recommend AC for patients with completely

Full access

Betsy L. Althaus

. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy . J Clin Oncol 2000 ; 18 : 2522 – 2528 . 7. Aapro MS Cameron DA Pettengell R . EORTC guidelines for the use of granulocyte

Full access

Benjamin M. Parsons, Dipesh Uprety, Angela L. Smith, Andrew J. Borgert and Leah L. Dietrich

No definite preferred standard of care exists for adjuvant chemotherapy (ACT) in patients with node-negative, HER2-positive breast cancers measuring <2 cm. 1 Prior to the advent of HER2-directed therapy, HER2 overexpression was a marker of poor

Full access

Marina Stasenko, R. Kevin Reynolds, Carolyn Johnston, Melissa Brackman, Karen McLean and Shitanshu Uppal

peritoneal cancers undergo treatment consisting of both surgical debulking and chemotherapy. Conventional chemotherapy includes intravenous carboplatin and paclitaxel administered every 3 weeks for 6 cycles. 2 The Gynecologic Oncology Group (GOG)-172

Full access

Pooja Ghatalia and Elizabeth R. Plimack

urinary tract. Approximately 50% of patients with localized UC experience recurrence after cystectomy and approximately 4% present with metastatic UC (mUC) at diagnosis. 2 Cisplatin-based chemotherapy remains the standard first-line treatment for mUC, with

Full access

Heike Reinhardt, Rainer Trittler, Alison G. Eggleton, Stefan Wöhrl, Thomas Epting, Marion Buck, Sabine Kaiser, Daniel Jonas, Justus Duyster, Manfred Jung, Martin J. Hug and Monika Engelhardt

professionals, with an increased demand for sterile production of chemotherapy drugs within existing workforce constraints. Resulting financial implications are also considerable. For the National Health Service (NHS) in England, for example, chemotherapy is the

Full access

Scott M. Schuetze and Michael E. Ray

adjuvant chemotherapy . Ann Surg 1982 ; 196 : 305 – 315 . 7 Potter DA Kinsella T Glatstein E . High-grade soft tissue sarcomas of the extremities . Cancer 1986 ; 58 : 190 – 205 . 8 Pisters PW Harrison LB Leung DH . Long

Full access

Saber Amin, Michael Baine, Jane Meza and Chi Lin

from NSCLC (12 months in targeted therapy vs 9 months in chemotherapy). 19 Median survival was improved by 16 months in patients with BMs from melanoma receiving a BRAF kinase inhibitor (21.3 vs 4.9 months). 20 A tyrosine kinase inhibitor improved

Full access

John P. Stoutenburg and Harry Raftopoulos

comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting . Eur J Cancer 1997 ; 33 : 66 – 74 . 2 Grunberg SM Hansen M Deuson R : Incidence and impact of nausea/vomiting with

Full access

Rosalyn A. Juergens and Arlene Forastiere

Edited by Kerrin G. Robinson

laparoscopy for staging esophageal cancer . Ann Thorac Surg 2007 ; 83 : 2000 – 2002 . 5. Medical Research Counsil Oesophageal Cancer Working Group . Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised